In August 2023, a lawsuit was filed against Novo Nordisk and Eli Lilly and Co., the manufacturers of Ozempic and Mounjaro, respectively
While the company did not publicly disclose specific reasons for discontinuation, the lack of statistically significant dose-response at Week 8 in the Phase 2b trial, likely contributed to the decision not to pursue further development in UC
Semaglutide was originally developed to manage blood sugar in people with type 2 diabetes, but clinical studies show it delivers significant cardiovascular benefits including cholesterol reduction
Wegovy Cardiovascular Risk-Reduction Indication
Consequently, diabetic subjects treated with GLP-1 receptor agonists often experience weight loss as opposed to the weight gain commonly induced with other treatment agents
If you want the full breakdown of how to compare those two numbers correctly, read Burst C Rating vs Continuous C Rating: What Actually Matters in a LiPo Battery